RCC2 and ovarian carcinoma: In summary, our studies found that RCC2 is often overexpressed in lung cancer and ovarian cancer, and RCC2 expression in cancer cells altered their sensitivity to drug-induced cell death, probably because of its interaction with cellular Rac1 activity.